17.7.2003: Meldung: EraGen Biosciences Announces Agreement with Aventis
The agreement centers on the use of EraGen""s Master Catalog product and its in-depth knowledge in evolutionary molecular biology. As a result, Aventis will have access to EraGen""s technical support group and expertise in this scientific discipline as it applies to Aventis"" target identification efforts.
Master Catalog is a genome centric software analysis system. It is unique in that it employs a patented genetic evolutionary technology to mine the genomic space for in silico protein prediction. The product predicts protein function by computing the evolutionary characteristics associated with 130 specific genomes including Pathogenome, GTC""s proprietary database, enabling rapid identification and prioritization of novel targets.
"EraGen is delighted to continue its collaboration with Aventis. We see the renewal of the Master Catalog license as validation of our products in their discovery efforts. We believe our distinct evolutionary approach to in silico protein prediction gives Aventis a competitive edge in the dynamic drug discovery market," commented Mark Meyers, vice president of sales and marketing for EraGen. "We are continually working to expand our commitment to the comparative genomics market, as can be seen with the launch of this expert services agreement. This agreement will leverage our intellectual property and our highly specialized staff for all of our Master Catalog customers."
About EraGen Biosciences
Based in Madison, Wisconsin, EraGen Biosciences is a rapidly growing life science company that designs, develops and commercializes innovative genetic based products in the diagnostics and drug discovery markets.
Further information is available at http://www.eragen.com/ or by telephoning 608-662-9000.